Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolex initiates Phase I study of diabetes drug
The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the
The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the
The double-blind, placebo-controlled efficacy study will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged
Under the agreement, Heraeus will manufacture picoplatin active pharmaceutical ingredient (API) to meet cGMP requirements, and be ready to ship commercial quantities of picoplatin by 2009. Heraeus is
This Phase III study is a multi-center, baseline-controlled, single dose study in which approximately 250 patients will receive an unenhanced magnetic resonance imaging (MRI) followed by a secretin-enhanced
Total disposable revenues were $2.8 million versus $3.0 million in the third quarter of fiscal 2008. Disposable revenues associated with the company’s core AXP AutoXpress Platform (AXP) and
Under the new agreement, HistoRx will provide Lilly researchers broad access to the Aqua technology for tissue biomarker analysis, and HistoRx will develop customized Aqua analysis-based immunohistochemical assays
In the study, scopolamine significantly reduced vigilance levels and cognition as measured by spectral analysis and Event Related Potentials (ERPs) respectively when administered to study subjects. The results
This study is a final key step in the company’s preparations to submit an investigational new drug (IND) application to the FDA in the third quarter in order
The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether sodium thiosulfate (STS) is an effective and safe means of preventing hearing
HT Hospital Technologies agreement calls for minimum sales of 150,000 units the first year, 200,000 units the second, and 250,000 units the third year. Robert McCullough, CEO of